Bausch & Lomb (BLCO) Q3 2025 Earnings
How Did BLCO Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: −1.04%.
Did BLCO Beat Earnings? Q3 2025 Results
Yes. Bausch & Lomb reported Q3 2025 earnings of $0.18 a share on Oct 29, 2025, beating the $0.16 consensus estimate by 11.9%. Revenue was $1.3B against a $1.3B estimate.
Bausch + Lomb delivered a solid third quarter, posting adjusted EPS of $0.18 against a consensus estimate of $0.16, a 12.50% beat, as broad-based revenue growth and improving operational efficiency carried the eye-health company ahead of expectations. Revenue rose 7.1% year-over-year to $1.28 billion, with all three segments contributing, led by Vision Care at $736.00 million and Pharmaceuticals at $330.00 million, the latter buoyed by strong uptake of MIEBO in the dry eye market. Operating income more than doubled to $95.00 million from $43.00 million a year ago, reflecting higher sales volumes and tighter expense management, though a swing in the tax provision pushed the GAAP result to a net loss of $28.00 million. Adjusted EBITDA climbed to $243.00 million from $212.00 million. Shares rose in pre-market trading on the profitability beat, and management reinforced confidence by narrowing full-year 2025 Adjusted EBITDA guidance to $870.00 million-$910.00 million while maintaining revenue guidance of $5.05 billion-$5.15 billion.
- Over-the-counter dry eye portfolio and eye vitamins growth in Vision Care consumer business
- Growth in SiHy Daily lenses and Biotrue ONEday in contact lens business
- Strong growth in MIEBO driving Pharmaceuticals segment
- International Pharmaceuticals growth
- Premium IOL growth in enVista and LUX platforms in Surgical segment
- Operating expense efficiencies
“We're delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories.”
Bausch & Lomb CEO, on the earnings call
What Was Bausch & Lomb's Outlook in Q3 2025?
Bausch + Lomb maintained full-year 2025 revenue guidance of $5.050B–$5.150B with approximately 5–7% constant currency growth. The company narrowed and raised the low end of its full-year 2025 Adjusted EBITDA excluding Acquired IPR&D guidance to $870M–$910M (from $860M–$910M previously), citing strong business performance. Full-year revenue foreign exchange tailwinds were increased to $30M from $25M due to U.S. dollar weakening. Adjusted EBITDA FX tailwinds remain nominal.
BLCO YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.3B | $1.2B | +7.1% |
| Gross Profit | $772.0M | $732.0M | +5.5% |
| Operating Income | $95.0M | $43.0M | +120.9% |
BLCO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.